3-Amino-4-phenylbutyric acid hydrochloride:Exports & Compliance White Paper 2026

I. Executive Summary

3-Amino-4-phenylbutyric acid hydrochloride (CAS 3060-41-1) is the hydrochloride salt of a phenyl-substituted gamma-amino acid: a butyric acid backbone carrying a phenyl group and a primary amine at adjacent positions, with a stereogenic centre at the substituted carbon. As the hydrochloride it is a crystalline, water-soluble and hygroscopic solid supplied as racemate or single enantiomer. This paper treats it strictly as a research and fine-chemical material for qualified institutional customers.

Two statements frame everything that follows. The compound has no approved therapeutic indication in any major jurisdiction, and material offered by responsible suppliers is labelled Research Use Only: not for human or veterinary use, not a finished consumer product, and not a recommendation for use as a dietary-supplement ingredient. This document accordingly provides no dosing, administration, effect or self-administration information, and it does not support consumer-facing or retail positioning. The commercial discussion is limited to custom synthesis, process development and scale-up, analytical method development and validation, and RUO-grade versus GMP-grade campaign design.

Because the molecule sits within the phenyl-GABA family and is structurally adjacent to phenibut-class and gabapentinoid chemotypes, it attracts elevated compliance screening, and several jurisdictions restrict phenibut-class substances outside prescription or licensed channels. Qualified supply therefore rests on Know-Your-Customer procedures, written end-use declarations, destination-legality checks and a quality system built on ICH Q7, Q11, Q3C and Q3D with HBEL-based containment. Buyers should expect verification before an order is accepted.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

The molecule combines a carboxylic acid, a primary amine and a lipophilic phenyl group in four carbons, and in solution it behaves as a zwitterionic amino acid whose hydrochloride salt form dominates handling. Protonation of the amine suppresses the volatility of the free base and improves crystallinity, at the cost of high hygroscopicity and of a chloride counter-ion that must be assayed rather than assumed.

• Salt form, hygroscopicity and solid-state control: The hydrochloride is freely soluble in water and sparingly soluble in most organic solvents, and it takes up moisture readily, so water content, loss on drying and chloride assay are specification items. Solid-form screening matters because absorbed water shifts the assay basis between lots. Buyers must specify whether they are qualifying the racemate or a single enantiomer, since that decision drives both the route and the analytical method.
• Chiral centre, related substances and stability: The substituted carbon is stereogenic, so enantiomeric purity is a defining attribute, and gamma-amino acids are prone to intramolecular cyclisation to lactams under heat and during prolonged solid-state storage. Development work therefore includes forced-degradation studies, a stability-indicating method, control of the lactam and isomeric amino-acid impurities, and confirmation that drying does not generate them.

2.2 Synthesis and Manufacturing Technologies

Suppliers discuss three route classes at the level appropriate to a CDMO quotation: carbonyl-condensation routes that build the skeleton first and install nitrogen late, conjugate-addition routes that set the stereocentre during carbon-carbon bond formation, and resolution-based routes that separate enantiomers once the skeleton is complete.

• Nitro and cyano route families: Classical approaches condense an aromatic aldehyde with a nitroalkane or use a nitroalkene Michael acceptor, then reduce the nitrogen functionality by catalytic hydrogenation and finish by hydrolysis and decarboxylation; variants install a nitrile and reduce it to the primary amine. These routes are short and cheap, and they place the analytical burden on residual nitro or nitrile intermediates, hydrogenation metals under ICH Q3D and residual solvents under ICH Q3C.
• Enantioselective and resolution-based routes: Where a single enantiomer is required, suppliers either resolve the racemate by diastereomeric salt formation or enzymatic methods, or set the stereocentre asymmetrically through catalytic hydrogenation or conjugate addition. They deliver the chiral specification directly but cost more, generate a mother-liquor stream containing the unwanted enantiomer, and require a validated chiral method from the first development batch.

2.3 Core Application Matrix

• Neuropharmacology and receptor research (Research Use Only): Institutional and industrial research groups buy the compound as a tool material for in-vitro and analytical work, typically in gram quantities with a certificate of analysis and an RUO statement. This use requires no therapeutic claim, and none is made or implied anywhere in this document.
• Analytical reference and impurity standards: Testing laboratories and compliance functions use characterised material as a reference or marker standard for identity confirmation and impurity profiling, where traceability, certified purity and water content matter more than price. Supply is small-volume and documentation-heavy, supported by a retained sample from each lot.
• CDMO custom synthesis and process development substrate: The compound is handled as a chiral amino-acid intermediate in process development programmes, where the deliverable is the route, the methods and the development report as much as the material. Campaigns run RUO or GMP depending on the customer's regulatory stage, and that choice determines containment, documentation and audit expectations.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand is small in tonnage and comes from three customer types: academic and institutional research procurement, analytical and compliance laboratories buying reference material, and pharmaceutical or biotech programmes that contract a CDMO for route development and campaign supply. Two shifts are visible in 2026. Laboratories increasingly require enantiomerically defined material with a stability-indicating method, and suppliers increasingly require an end-use declaration before shipping, because phenibut-class substances are regulated in several destination markets. Volume therefore tracks research funding and compliance activity.

3.2 Capacity Distribution and Export Flows

China supplies the largest share of catalog and research-grade material, with amino-acid and fine-chemical capacity able to quote racemic and resolved grades. India's role is CDMO-centred, with custom-synthesis and process-development groups in Hyderabad, Bengaluru and Gujarat running campaigns inside customer programmes under ICH Q7 and Q11, supported by FDA- and EMA-inspected sites. The European Union, and to a lesser extent the United States, hosts smaller, higher-cost capacity oriented to reference-standard production and analytical method development. Flows run from Asia to Western laboratories, with the documentation package determining whether customs and the customer release a shipment.

3.3 Market Bifurcation and Pricing Dynamics

Pricing is quotation-based and dominated by specification. A racemic RUO grade with a basic certificate of analysis is a commodity-priced research chemical, while an enantiomerically defined GMP-campaign lot with a validated chiral method, elemental-impurity screening, residual-solvent testing and a full development report can cost an order of magnitude more per gram. Buyers should normalise offers on specification, documentation scope and containment, because a low quotation often means an unvalidated assay and no retained sample. Compliance screening also affects lead time, since end-use verification precedes order acceptance at responsible suppliers.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

For this compound, compliance is not a downstream formality: it determines whether an order is accepted at all. Suppliers that treat end-use verification as optional create diversion risk and regulatory exposure.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH, CLP and food-law boundaries: Where the substance is placed on the EU market, registration or coverage by a registration, an only representative for non-EU manufacturers, and a CLP-aligned classification and safety data sheet are prerequisites. Separately, the compound has no authorised use as a food or food-supplement ingredient in the EU, so presenting it as a dietary ingredient would engage Novel Food Regulation (EU) 2015/2283 and national controls. Buyers should confirm that the intended-use declaration matches a legitimate research or industrial purpose.
• National controls on phenibut-class substances: Several member states and several non-EU jurisdictions treat phenibut-class substances as prescription-only or prohibited outside licensed channels, and the legal position differs by country and changes over time. Exporters must run a destination-legality check against current national lists before quoting, record the result, and decline orders that cannot be reconciled with the destination's rules.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• TSCA status and FDA position: Confirm active TSCA Inventory listing for CAS 3060-41-1 before first shipment, hold written inventory-status certification and check any Chemical Data Reporting obligation. On the FDA side there is no approved new drug application for this compound and no established dietary-ingredient status, so supply positioned as a finished consumer product or supplement ingredient is not supportable, and material shipped for research must carry an end-use declaration.
• ICH expectations for GMP campaigns and method validation: Where a customer requires GMP supply, the campaign runs under ICH Q7, the route and starting-material selection are described under ICH Q11, impurity and solvent control follows ICH Q3C and Q3D, and analytical methods are validated to ICH Q2 expectations. For RUO campaigns the same frameworks apply proportionately, but the supplier should still state which methods are validated and which are development-grade.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

ESG expectations follow the customer's own reporting duties, and for a small-volume research compound they concentrate on solvents, containment waste and documentation rather than on energy.

5.1 Carbon Footprint and Circular Economy

The footprint is set by solvent use and by the number of isolations in a multi-step amino-acid synthesis. Reducing step count, recovering solvents by distillation and avoiding repetitive isolations are the credible levers, and customers increasingly ask for process mass intensity per campaign. Suppliers should hold ISO 14001 certification, report Scope 1 and 2 inventories under ISO 14064 or the GHG Protocol, and describe how solvent wastes are treated.

5.2 Sustainable Sourcing and Traceability

Traceability requirements are pharmaceutical-grade even for RUO material: batch genealogy from starting material to released lot, certificates of analysis for each input, retained samples, and a documented chain of custody that supports the end-use declaration. Customers increasingly ask for responsible-sourcing declarations and modern-slavery statements. Because campaigns often share equipment, buyers should confirm whether a train is dedicated or multipurpose and require the cleaning-validation summary that follows.

VI. Supply Chain Resilience and Export Logistics

The hydrochloride is a stable but hygroscopic crystalline solid, so logistics risk concentrates on moisture ingress, labelling and documentation rather than on temperature.

6.1 Packaging Standards and Moisture/Contamination Control

• Moisture-barrier packaging and chloride control: Pack in double polyethylene liners inside HDPE or glass containers with desiccant, sealed under nitrogen where specified; avoid paper contact. Specify water content, loss on drying, chloride assay and appearance at release, and set a defined retest period with a stated temperature ceiling rather than an open ambient shelf life.
• Labelling, documentation and chain of custody: Every container should carry the Research Use Only statement, the CAS number, the lot number, the storage condition and the retest date, and every shipment should be accompanied by a certificate of analysis with actual batch values, a safety data sheet and a copy of the accepted end-use declaration. Suppliers should retain samples and be able to reconstruct which customer received which lot.

6.2 Dangerous Goods Identification and Transit Protocols

Most shipments are not dangerous goods, but the classification must come from the current SDS for the exact salt form, since amine hydrochlorides can attract irritant classification. Where a classification applies, IMDG, ADR/RID and IATA rules govern packaging, marking and documentation; where it does not, the controls are moisture-barrier packaging, desiccant and sealed liners. No cold chain is required for the salt, although cool, dry and temperature-logged transport is sensible for long sea routes and humid ports. Air freight is common for gram-scale research orders, and customs documentation should be prepared in advance.

VII. Enterprise Global Expansion Strategy Guide

Three actions determine whether a buyer obtains lawful, usable and auditable supply.

1. Complete Know-Your-Customer and end-use verification first: Provide institutional status, intended research or industrial purpose and destination, and expect the supplier to verify them before accepting the order. This is not a formality: suppliers who skip it create diversion risk and regulatory exposure for both parties.
2. Define the analytical package and its validation status: Require a validated chiral HPLC or SFC method for enantiomeric purity, a stability-indicating related-substances method covering the lactam and amino-acid impurities, ICP-MS for ICH Q3D elements, GC for ICH Q3C solvents, and stated water and chloride results. Agree which methods are validated before the first batch and require change-control notification.
3. Set containment and campaign grade before quoting: Ask for the assigned health-based exposure limit and occupational exposure band, the containment measures that follow from them, and cleaning limits derived from the PDE or ADE. Decide explicitly whether the campaign is RUO or GMP, since that sets documentation depth, audit expectations and price.

VIII. Conclusion

This compound is best understood as a compliance-managed research material rather than as a product. Its chemistry is straightforward, so what separates a usable supplier from an unusable one is the willingness to apply RUO labelling, end-use verification and destination-legality checks, to measure enantiomeric purity with a validated method, and to assign a health-based exposure limit. Buyers who build those requirements into the enquiry receive comparable quotations and defensible supply.

The outlook is stable. Research and reference-standard demand continues, the drift toward enantiomerically defined material with validated methods is strengthening, and the Chinese, Indian and European ecosystems serve different needs: catalog and research-grade capacity in China, programme-integrated custom synthesis in India, and reference-standard and early-phase GMP capability in Europe. Supply arrangements pairing that specialisation with written end-use declarations and HBEL-based containment will remain auditable as controls evolve.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global 3-Amino-4-phenylbutyric acid hydrochloride Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global 3-Amino-4-phenylbutyric acid hydrochloride supply chain:

• China - catalog and research-grade capacity: The largest source of merchant research material, concentrated in Jiangsu, Shandong, Zhejiang and Shanghai, with amino-acid producers able to quote racemic and resolved grades quickly. Strengths are speed, breadth and price; watch points are the validation status of the chiral method and whether certificates report measured values.
• India - programme-integrated CDMO capacity: Centred on Hyderabad, Bengaluru and Gujarat, where the compound is made inside customer programmes rather than sold as catalog stock. Strengths are ICH Q7 and Q11 experience, inspected sites and route-development capability; watch points are lead time and cost per gram.
• European Union - reference standards and early-phase GMP: Smaller and more expensive, but strongest where the customer needs characterised reference material or a documented GMP campaign. Strengths are mature REACH and CLP practice, ISO certification, validated method development and conservative compliance screening; constraints are cost and volume appetite.